Nanchahal; Jagdeep

Patent Applications and Registrations

Patent applications and USPTO patent grants for Nanchahal; Jagdeep.The latest application filed is for "method of treating dupuytren's disease using a pre-filled syringe".

Company Profile

9.8.20

Nanchahal; Jagdeep - Headington GB
Nanchahal; Jagdeep - Oxford GB
Nanchahal; Jagdeep - Richmond Surrey GB
Nanchahal; Jagdeep - Richmond GB
Nanchahal; Jagdeep - London GB

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Method of treating a localized fibrotic disorder using an IL-33 antagonist Grant 11,400,154 - Larsen , et al. August 2, 2	2022-08-02
Method of Treating Dupuytren's Disease Using A Pre-filled Syringe App 20220235125 - Nanchahal; Jagdeep ; et al.	2022-07-28
Methods For Reducing Post-operative Cognitive Dysfunction (pocd) App 20220112281 - Maze; Mervyn ; et al.	2022-04-14
Prophylactic And Therapeutic Uses Of Fully Reduced Forms Of Hmgb1 In Conditions Involving Organs App 20220023387 - Nanchahal; Jagdeep ; et al.	2022-01-27
Methods for reducing post-operative cognitive dysfunction (POCD) Grant 11,220,540 - Maze , et al. January 11, 2	2022-01-11
Method Of Treating A Localized Fibrotic Disorder Using A Tnf Receptor 2 Antagonist App 20210386855 - Larsen; Glenn ; et al.	2021-12-16
Prophylactic Uses Of Partially Or Fully Reduced Forms Of Hmgb1 Prior To Injury App 20210260157 - Nanchahal; Jagdeep ; et al.	2021-08-26
Method Of Treating Early Stage Dupuytren's Disease App 20210040196 - NANCHAHAL; Jagdeep ; et al.	2021-02-11
Method Of Treating A Localized Fibrotic Disorder Using An Il-33 Antagonist App 20200338193 - Larsen; Glenn ; et al.	2020-10-29
Treatment for Dupuytren's disease Grant 10,669,334 - Nanchahal , et al.	2020-06-02
Method of treating a localized fibrotic disorder using an IL-33 antagonist Grant 10,500,273 - Larsen , et al. Dec	2019-12-10
Treatment For Dupuytren's Disease App 20190322733 - Nanchahal; Jagdeep ; et al.	2019-10-24
Method Of Treating Localized Fibrotic Disorders Using An Il-33/tnf Bispecific Antibody App 20190225682 - Nanchahal; Jagdeep ; et al.	2019-07-25
Method Of Treating Systemic Fibrotic Disorders Using An Il-33/tnf Bispecific Antibody App 20190202907 - Nanchahal; Jagdeep ; et al.	2019-07-04
Treatment for dupuytren's disease Grant 10,273,296 - Nanchahal , et al.	2019-04-30
Method Of Treating A Localized Fibrotic Disorder Using A Tnf Receptor 2 Antagonist App 20180036404 - Larsen; Glenn ; et al.	2018-02-08
Method Of Treating A Localized Fibrotic Disorder Using An Il-33 Antagonist App 20180030130 - Larsen; Glenn ; et al.	2018-02-01
Treatment For Dupuytren's Disease App 20160280775 - Nanchahal; Jagdeep ; et al.	2016-09-29
Treatment for dupuytren's disease Grant 9,138,458 - Nanchahal , et al. September 22, 2	2015-09-22
Methods for Improving Fracture Healing and Bone Formation App 20140056960 - Nanchahal; Jagdeep ; et al.	2014-02-27
Treatment For Dupuytren's Disease App 20130287760 - Nanchahal; Jagdeep ; et al.	2013-10-31
Use of Pro-Inflammatory Compounds for Promoting Bone Formation App 20120213826 - Nanchahal; Jagdeep ; et al.	2012-08-23

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.